Francesco Paolo T.
- Country
- Italy
- Department
- Dipartimento di Oncologia, Ematologia e Terapia Cellulare
Research Overview
Data & Insights
Has run more than one trial at 6 of 74 partner sites.
Specializations
Paediatric acute leukaemias
Clinical research activity is centred on acute lymphoblastic leukaemia, acute myeloid leukaemia, acute promyelocytic leukaemia, and relapsed or refractory B-cell precursor ALL, with interest in Philadelphia chromosome-positive and ABL-class Ph-like disease.
- Chemo-immunotherapy for relapsed and high-risk ALL
- Targeted therapy in FLT3-mutated AML and BCR::ABL1-rearranged disease
- Minimal residual disease and relapse-focused treatment strategies
The therapeutic landscape also includes blinatumomab, inotuzumab ozogamicin, midostaurin, ponatinib, and revumenib, reflecting a strong focus on precision treatment in childhood haematologic malignancies.
Haematopoietic stem cell transplantation and graft-versus-host disease
Research involvement extends to HSCT in paediatric ALL, conditioning regimens, and post-transplant disease control, alongside management of acute graft-versus-host disease and relapse prevention.
- Transplant conditioning optimisation in ALL
- GVHD prophylaxis and treatment
- Post-transplant maintenance strategies
Key therapeutic interests include ruxolitinib for acute GVHD and blinatumomab in the post-transplant setting, with attention to reducing toxicity while preserving anti-leukaemic control.
Paediatric solid tumours and neuro-oncology
The investigator is active in trials for neuroblastoma, Ewing sarcoma, osteosarcoma, rhabdomyosarcoma, medulloblastoma, ependymoma, glioma, diffuse intrinsic pontine glioma, and atypical teratoid/rhabdoid tumours.
- High-risk neuroblastoma treatment intensification
- Relapsed sarcoma and metastatic bone tumour therapy
- Central nervous system tumours in children and adolescents
Therapeutic interests include radiotherapy, high-dose chemotherapy, immunotherapy, and targeted agents such as tovorafenib and abemaciclib.
Inherited bleeding disorders and immune-mediated neuromuscular disease
Clinical work also covers haemophilia A, von Willebrand disease, and generalized myasthenia gravis, reflecting involvement in both haemostatic and autoimmune therapeutic areas.
- Bleeding control in paediatric coagulation disorders
- Factor replacement and non-factor therapy
- Immunomodulatory treatment for myasthenia gravis
Relevant agents include emicizumab, vonicog alfa, and rozanolixizumab, with interest in improving symptom control and long-term disease management in children.
Burn care and regenerative skin repair
Another area of activity is the treatment of deep partial-thickness and full-thickness burns, as well as large skin defects requiring reconstructive care.
- Skin grafting for extensive tissue loss
- Wound closure in paediatric burn injury
- Scar reduction and tissue regeneration
Research interest includes engineered skin substitutes such as denovoSkin™ and EHSG-KF, highlighting a therapeutic focus on restorative approaches in paediatric reconstructive medicine.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.